LA
Luís Aguiar
Clinical Research Associate at Evidenze Portugal
View Luís's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Clinical Research Associate
Jun 2021 - Present · 3 years and 7 months
President Of The Supervisory Board
Sep 2021 - Present · 3 years and 4 months
Company Details
11-50 Employees
We are Evidenze Clinical Research, previously Keypoint. We are a full-service CRO, dedicated to the development and implementation of clinical trials, observacional studies, record studies, epidemiological studies, economic evaluation studies, pharmaceutical surveillance, regulation affairs, medical writing, data management and biostatistics. Founded in 1999, being a private capital firm , exclusively national. We iniciated our activity in 2003, obtaining in 2004 Certification by ISO 9001-2000. Throughout our course, we has been improving continuously the quality of services in all areas, permanently adjusting ideas and solutions according to constantly market changes. We are Evidenze. We are partners of the Healthcare sector. We understand that our role is to help our clients fulfill their transformation visions. That is why we offer services in all phases of the life cycle of a product, whether they are specific solutions, or global solutions that combine the expertise of our different units: Clinical Research, Medical Education, Digital Health, Patient Support, Scientific Events, Communication and Data Services.
Year Founded
1999
Social Media
Linkedin
Industry
Pharmaceutical Manufacturing
HQ Location
Alameda Fernão Lopes, nº16A 7º andar - Escritório 1 Miraflores, Algés 1495-190, PT
Keywords
HealthEpidemiological StudiesClinical TrialsObservacional StudiesBiostatisticsMedical WritingData ManagementRegistry studiesAdvisory Boardsand Health Communication
Discover More About Cleveland Clinic

Find verified contacts of Luís Aguiar in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.